ASXL1

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Retrieved on: 
Thursday, March 7, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapy, NSCLC, Investigational New Drug, Bone marrow, AML, RUNX1, Cancer, B-cell lymphoma, ASXL1, Clinical Cancer Research, Classification, Patient, CERO, IND, Cero, Vaccine

The results in the paper found that the target for CER-1236 is found in the large majority (83%) of leukemic cells extracted from the bone marrow from patients, and that more importantly CER-1236 effectively eliminated leukemic cells in the company’s experiments.

Key Points: 
  • The results in the paper found that the target for CER-1236 is found in the large majority (83%) of leukemic cells extracted from the bone marrow from patients, and that more importantly CER-1236 effectively eliminated leukemic cells in the company’s experiments.
  • Finally, the target for CER-1236 was found by CERo to be highly expressed and detectable across common AML genetic classification subtypes, including patient samples with adverse risk mutations in TP53, ASXL1 and RUNX1.
  • “We’re very pleased with this publication in Clinical Cancer Research supporting our near term plans to advance CER-1236 into the clinic.
  • As we have previously reported, CERo plans to file an Investigational New Drug (IND) application in the first half of 2024, and is targeting initial treatment of AML patients as well as B Cell lymphoma patients before the end of the year,” said Brian G Atwood, CERo’s Chairman and Chief Executive Officer.

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, International Prognostic Scoring System, IPSS, Survival, FDA, RUNX1, H. Lee Moffitt Cancer Center & Research Institute, VAF, Food, TP53, Thrombocytopenia, Literature, EZH2, MDS, European Medicines Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Imetelstat, Society, ASXL1, SF3B1, Transfusion-dependent anemia, Geron Corporation, Risk, Abstract, TI, EMA, Corporation, LR, Anemia, ETV6, Patient, Neutropenia, Mutation, Pharmaceutical industry, Communications satellite, ASH

Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.

Key Points: 
  • Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.
  • “Additionally, our abstract showcasing a real-world data population level analysis of over 5,000 lower risk MDS patients adds to the significant literature suggesting a correlation between TI and improvement in survival.
  • This analysis suggests imetelstat has clinical activity in lower risk MDS patients independent of risk categories.
  • Achievement of durable TI was associated with improved survival, supporting the clinical benefit of achieving transfusion independence in lower risk MDS.

Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Retrieved on: 
Wednesday, June 14, 2023
Myelodysplastic syndrome, Pathology, Diagnosis, WT1, Health, ASXL1, History, Transfusion-dependent anemia, Medical imaging, Omnia, HAVEN

The findings point to an underlying myeloid stem cell disorder, including a myelodysplastic syndrome and possibly a higher-grade myeloid neoplasm.

Key Points: 
  • The findings point to an underlying myeloid stem cell disorder, including a myelodysplastic syndrome and possibly a higher-grade myeloid neoplasm.
  • A major advantage in the case work-up using the Omnia methodology was the ability to detect these driver mutations using only a peripheral blood sample and not requiring a further bone marrow biopsy to confirm pathology suspicions.
  • “Providing a comprehensive diagnosis with minimally invasive sample procurement is critical to informing treatment decisions,” said Ilan Danieli, Precipio CEO.
  • “Not only does this enable our lab to deliver a rapid diagnosis, but greatly improves patient compliance from those who would otherwise need a more invasive, follow up bone marrow biopsy to confirm results.”

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, Abstract, TET2, DNA, European Hematology Association, TI, Imetelstat, Chromosome, Infection, RNA, VAF, MDS, Corporation, ASXL1, Geron Corporation, Patient, Risk, CEST, Cytopenia, EHA, Public, RS, Transfusion-associated circulatory overload, DNA methylation, Gene, Thrombocytopenia, RNA splicing, Fatigue, Pharmaceutical industry, DNMT3A, SF3B1

The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.

Key Points: 
  • The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.
  • As reported in January, 39.8% (47/118) of imetelstat-treated patients versus 15.0% (9/60) of placebo-treated patients achieved the study primary endpoint of 8-week TI (P
  • As noted in the abstract, a main therapeutic goal in lower risk MDS is to alter disease biology by eradicating malignant clones.
  • Of the 178 patients enrolled in IMerge Phase 3, 22.0% of imetelstat-treated patients and 21.7% of placebo-treated patients had baseline cytogenetic abnormalities.

Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Retrieved on: 
Wednesday, January 4, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Hematology, Weakness, MF, Anemia, Food, TI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, LFT, Peripheral edema, DNMT3A, Diarrhea, NDA, ESA, Reverse transcriptase, Risk, Cytopenia, Disease, ASXL1, Patient, Imetelstat, IWG, Febrile neutropenia, Infection, Mutation, Brain Quest Grades 3 & 4, Safety, Marketing, Neutropenia, Headache, MAA, Thrombocytopenia, MDS, TET2, Fast Track, Pharmaceutical industry, EU

Imetelstat patients also experienced a statistically significant (p=0.042) and clinically meaningful mean reduction in RBC transfusion units compared to placebo.

Key Points: 
  • Imetelstat patients also experienced a statistically significant (p=0.042) and clinically meaningful mean reduction in RBC transfusion units compared to placebo.
  • “The notable results from IMerge Phase 3 underscore our belief that, with the unique mechanism of action of imetelstat as a telomerase inhibitor, the drug has the potential to become a first-in-class therapy for lower risk MDS patients.
  • “The IMerge Phase 3 efficacy results illustrate the depth, breadth and durability of transfusion independence potentially achievable with imetelstat treatment, which could be practice changing, if approved.
  • A conference call with Geron management to review the IMerge Phase 3 top-line results is scheduled at 8 a.m. Eastern Time this morning and may be accessed on Geron’s website.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022

Retrieved on: 
Monday, December 12, 2022
ASXL1, Dysgeusia, Pancreatic serous cystadenoma, European Medicines Agency, EMA, Intellectual property, Sumathi Best Television Current Reporting Award, Annual report, MF, Week, TSS, Congress, Sale, AE, EHA, Safety, Bone marrow, Hematology, Cancer, JAK2, ET, Priority, Trial of the century, Good manufacturing practice, ASH, HMR, MAF, Blood, AML, Acute myeloid leukemia, Șaeș, Fibrosis, Society, Ruxolitinib, LSD1, Fast track (FDA), Patient, Anemia, Pharmaceutical industry, Imago

REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).

Key Points: 
  • (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
  • The data were presented in a poster presentation session during the 64th American Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022.
  • A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30th European Hematology Association Annual Meeting and congress (EHA) in June 2022.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185).

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022

Retrieved on: 
Friday, June 10, 2022
HMR, Congress, Company, Married at First Sight (American TV series), Ruxolitinib, Sale, COVID-19, Omicron, European Medicines Agency, Cancer, Polycythemia, Pancreatic serous cystadenoma, Ageing, CEO, Lists of disasters, ET, MF, Blood, JAK, Queen Mary's Hospital, Trial of the century, Bone marrow, Patient, United Kingdom, EMA, Anemia, Priority, Annual report, Webcast, TSS, Transient myeloproliferative disease, AML, Fast Track, Compliance, JAK2, EHA, Leukemia, Mutation, Private Securities Litigation Reform Act, Fibrosis, LSD1, Facebook, Society, ASH, Week, LinkedIn, Department of Medicine – University of Pamplona, Disease, Growth, GLOBE, Risk, Pandemic, SAN, University of Hong Kong, Hospital, Safety, Pharmaceutical industry, Animal, Imago, ASXL1

SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).

Key Points: 
  • (Imago or the company) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
  • The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA), taking place 9-12 June 2022.
  • The potential of bomedemstat to be a unique and differentiated monotherapy for patients living with advanced myelofibrosis is underscored by the data presented at EHA today, saidHugh Young Rienhoff, Jr., M.D., CEO of Imago.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia ( NCT04254978 ) and myelofibrosis ( NCT03136185 ).

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

Retrieved on: 
Monday, May 2, 2022
Drug development, Toxicity, Monocyte, Lymphoid leukemia, Risk, Chronic lymphocytic leukemia, Skin, Exchange, Microdeletion syndrome, Cell death, TSX, APS, Phosphorylation, NLRP3, NASDAQ, PDX, Mantle cell lymphoma, Mitophagy, Company, Patient, SYK, Research, Inflammation, SAN, Therapy, CLL, Venetoclax, IL-6, BTK, Inflammasome, TP53, Acute myeloid leukemia, RAS, GMP, TEC, ERK, Publication, Hematology, MDS, NHL, U.S. Securities and Exchange Commission, LYN, Toxic epidermal necrolysis, COVID-19, Cytokine, ERBB2, NPM1, AML, GLOBE, MCL, Apoptosis, Cancer, Lymphatic system, EGFR, TLR, ASXL1, American Association for Cancer Research, THP-1 cell line, Pharmaceutical industry, Vaccine, Sulfur, Food preservation, FLT3

Luxeptinib does not impede the assembly of the NLRP3-ASC complex but does potently inhibit three kinases phosphorylated in response to endotoxin.

Key Points: 
  • Luxeptinib does not impede the assembly of the NLRP3-ASC complex but does potently inhibit three kinases phosphorylated in response to endotoxin.
  • Luxeptinib also inhibits the release of TNF and IL-6 in response to activation of the TLR pathway without affecting the TLR/IRAK/MyD88 proteins.
  • Luxeptinib induced apoptosis in ibrutinib-resistant MCL cell lines, and in primary MCL cells luxeptinib downmodulated anti-apoptotic proteins Mcl-1 and Bcl-xL and reversed stromal cell survival effects.
  • Oral luxeptinib demonstrated strong antitumor activity in preclinical in vivo AML xenograft models but no myelosuppression or evidence of tissue damage in acute toxicology studies.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

Retrieved on: 
Saturday, December 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Congress, Ageing, University of Hong Kong, LinkedIn, AML, Married at First Sight (American TV series), Facebook, Program, CMO, ASXL1, CEO, ASH, Department, Exposition, Queen Mary's Hospital, LSD1, Patient, Trial of the century, Bone marrow, JAK, Blood, Anemia, Cancer, HMR, Department of Medicine – University of Pamplona, University, Priority, Safety, European Medicines Agency, European Hematology Association, EMA, ET, Society, TSS, Pancreatic serous cystadenoma, Ruxolitinib, Private Securities Litigation Reform Act, Disease, MF, Pharmaceutical industry, Residential care, Imago’s Phase 2 Advanced Myelofibrosis Program, Imago BioSciences, IMAGO’S PHASE 2 ADVANCED MYELOFIBROSIS PROGRAM, IMAGO BIOSCIENCES

(Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).

Key Points: 
  • (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
  • The data were presented in an oral session during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021.
  • Previously, a Phase 2 data set with a cut-off date of May 17, 2021 was presented at the European Hematology Association 2021 Virtual Congress.
  • Todays ASH 2021 data further demonstrates the potential of bomedemstat as a unique and differentiated treatment option for patients living with advanced myelofibrosis, said Wan-Jen Hong, M.D., CMO, Imago BioSciences.